簡報大綱

Immuno-oncology (aka IO) has been a critical sector of cancer therapy since the 1990s. There are two subsectors that especially catch the eyes of investors these years, they are immune checkpoint inhibitors (aka ICI) and immune cell therapies.

So far, there are nine ICIs approved by FDA since 2011, seven of them belong to  PD1/PDL1 series, one belongs to CTLA-4 and the latest approved targets LAG3. Most of these ICIs are used in combination with the other therapeutics agents because ICIs only work well on about 20~30% of the cancer population.
On the other hand, we have seen the magic of CAR-T (one of the immune cell therapies).  This living drug can even cure the deadly disease that humans never thought that they would be capable of vanquishing.

Though powerful, there are still unmet needs to be fulfilled and adverse side effects to be overpowered for ICIs and immune cell therapies. In this talk, I would like to deliver.

1. Briefing on the global IO therapies industry & trends
2. Overview of domestic industry on IO development
3. Discuss the IO development strategies for the Taiwan biotech industry
    

簡報內容